Business Context and Reporting Period
This Form 8-K was filed by TriSalus Life Sciences, Inc. (TLSI) on August 13, 2024. The report primarily covers the results of the Company's 2024 Annual Meeting of Stockholders held on August 13, 2024, and references a business update and financial results press release issued on August 15, 2024, for the quarter ended June 30, 2024.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes and Voting Results
The filing details the outcomes of two proposals voted upon by stockholders at the Annual Meeting. The aggregate voting power of outstanding shares entitled to vote was 31,455,515 as of the June 26, 2024 record date.
Proposal 1: Election of Directors
Stockholders elected four Class I directors to serve until the 2027 Annual Meeting. The voting results were as follows:
| Director Name | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Anil Singhal | 15,581,603 | 53,394 | 2,206,892 |
| Kerry Hicks | 15,552,616 | 82,381 | 2,206,892 |
| Liselotte Hyveled | 15,586,944 | 48,053 | 2,206,892 |
| Sean Murphy | 15,611,916 | 23,081 | 2,206,892 |
Proposal 2: Ratification of Auditors
Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|
| 17,841,461 | 427 | 1 | - |
Guidance, Outlook, and Risks
The filing references a press release containing a business update and financial results but does not include specific guidance, outlook, management commentary, or risk factors within the text of this 8-K. The information in Item 2.02 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Financial Data Source: Specific Q2 2024 financial metrics (revenue, net loss, cash position) are not in this text; investors must review Exhibit 99.1 (Press Release dated August 15, 2024).
- Board Composition: Four directors were successfully re-elected for Class I seats, with significant broker non-votes (approx. 2.2 million shares) recorded for each candidate.
- Auditor Ratification: Grant Thornton LLP was overwhelmingly ratified as the independent auditor.
- Emerging Growth Status: The Company is identified as an emerging growth company.